Talented team and industry-leading lab will help strengthen the company’s sequencing and pipeline capabilities, while broadening its therapy selection and treatment guidance offerings.
Category Archives: AZBio News
BD Announces 510(k) Clearance of Pristine™ Long-Term Hemodialysis Catheter
Clearance supported by clinical data from a feasibility study with favorable primary patency rates observed out to 180 days Pristine™ Long-Term Hemodialysis Catheter
Fruit Flies and Cellular Demise – Zeroing in on the Causes of ALS
New UArizona research has identified a previously unknown pattern of protein creation in the motor neurons, which are the cells that malfunction in patients with ALS. By restoring the missing proteins at one end of the cell, movement returns. Next, the team hopes to determine if the surprising over-production at the other end of the cell also has consequences.
Arizona’s bioscience community reports on ‘a robust industry cluster’
The Flinn Foundation hosted its annual bioscience event April 14 to share the impressive progress of Arizona’s growing sector nearly two decades since the launch of Arizona’s Bioscience Roadmap.
The virtual event featured a keynote address by Tom Osha of Wexford Science and Technology and a mix of live presentations and videos showcasing the innovative and growing bioscience ecosystem throughout Arizona, including Flagstaff, metro Phoenix, and the Tucson and Yuma regions. Continue reading
FCC to Award Additional $250M in Funding COVID-19 Telehealth Program
Applications for the 2021 FCC Telehealth Program are expected to open soon. Life365 is providing information and resources to help qualified healthcare organizations get started with their applications.
Continue reading
TGen identifies gene that could help prevent or delay onset of Alzheimer’s disease
Boosting ABCC1 could lessen the production of plaque linked to Alzheimer’s development
PHOENIX, Ariz. — April 13, 2021 — Findings of a study by the Translational Genomics Research Institute (TGen), an affiliate of City of Hope, suggest that increasing expression of a gene known as ABCC1 could not only reduce the deposition of a hard plaque in the brain that leads to Alzheimer’s disease, but might also prevent or delay this memory-robbing disease from developing.
Vaccine Navigators Available to Assist Medicaid Members with Appointment and Transportation Scheduling
The Arizona Health Care Cost Containment System (AHCCCS), in partnership with Crisis Response Network, announces a new COVID-19 appointment and transportation navigation program for Medicaid members. Now, Medicaid members who need assistance scheduling a COVID-19 vaccine appointment, as well as transportation to and from that appointment, can call 1-844-542-8201, 8 a.m. to 5 p.m., seven days a week.Continue reading
Calviri Appoints Marc Wolff Chief Executive Officer
PHOENIX–(BUSINESS WIRE)–Calviri announces the appointment of Marc Wolff as Chief Executive Officer. Founder and current CEO, Stephen Albert Johnston, will continue to serve as Chairman of the Board of Directors and Founding CEO.Continue reading
C-Path’s Alzheimer’s Disease Consortium Expands Data Repository
New patient-level data will facilitate more efficient clinical trial design
OncoMyx Presents at AACR First Data Showing Multi-Armed Myxoma Virotherapy Can Modulate Anti-Tumor Immune Response
OncoMyx’s multi-armed myxoma virotherapy upregulates genes associated with immune response and shows modulation of the immune response to favor anti-tumor immunity
vMYX-hIL-12/Dec produces functional protein (hIL-12) from transgenes in vivo and in a dose and time responsive in vitro and has demonstrated anti-tumor efficacy in a xenograft human lung cancer model
Quantitative systems pharmacology modeling suggests IV administration of multi-armed myxoma virotherapy to fall within known safety margins at the planned doses of oncolytic immunotherapiesContinue reading